Atlas Trials

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

Clinical trial NCT06323369 · RECRUITING

Trial details

NCT number
NCT06323369
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Head and Neck Squamous Cell Carcinoma
Start date
2024-03-25
Primary completion
2029-03-25
Enrollment
154

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.